Greenlane announces board approval of reverse stock split ratio
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
41 minutes ago
- Business Insider
‘Make a Fast Exit,' Says Top Investor About Palantir Stock
Some companies are riding the AI wave — and then there's Palantir (NASDAQ:PLTR) stock, practically surfing it into the stratosphere with a whopping 538% gain over the past year. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. That surge has been fueled by results that keep smashing expectations. In its Q2 2025 earnings release last week, Palantir not only crossed the $1 billion revenue mark for the first time, but also showed no signs that its white-hot momentum is cooling. While defense-related government contracts remain its bread and butter, U.S. commercial revenue soared 93%, underscoring that PLTR is firing on all cylinders. But eye-popping numbers can also draw sharp scrutiny. One top investor, known by the pseudonym JR Research, warns that the growth party may be nearing its peak – and that overoptimistic bulls could be in for a harsh reality check. 'With PLTR's growth rate potentially peaking this year, the market momentum could reverse to the downside, ensnaring the overoptimistic bulls,' who is among the very top 1% of TipRanks' stock pros. JR acknowledges the company's strong fundamentals, including a recent $10 billion, 10-year deal with the U.S. Army, but questions whether Wall Street's sky-high expectations are sustainable. With valuations approaching a staggering 250x P/E, JR suggests the stock's rally assumes a 'never-ending' pace of growth, which he doubts is realistic. 'Don't you think that when the chickens come home to roost, the pain might also be as equally 'intense' as the excitement that was felt on the way up?' the investor asks, advising both current and would-be investors to tread carefully, or consider exiting altogether. (To watch JR Research's track record, click here) Wall Street isn't as blunt, but skepticism is still in the air. The consensus rating sits at Hold, with 13 analysts on the sidelines versus just 4 Buys and 2 Sells. The average 12-month price target of $152.12 implies ~19% downside from current levels. (See PLTR stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
42 minutes ago
- Yahoo
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ('Nyxoah' or the 'Company'), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates. Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S. Food and Drug Administration (FDA) has approved the Genio® system for a subset of adult patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65. Press Releases | Nyxoah Investors Revenue for the second quarter of 2025 is anticipated to be approximately €1.3 million, a 73% increase over the second quarter of 2024. Operating expenses for the second quarter of 2025 are anticipated to be approximately €20.7 million, a 50% increase over the second quarter of 2024. Cash, cash equivalents and financial assets are anticipated to be approximately €43.0 million at June 30, 2025. The Company also has a term debt facility with €27.5 million of remaining availability which can be drawn down in two equal tranches subject to revenue and other financial milestones. The Company expects to close patient enrollment in its ACCCESS clinical trial prior to enrolling all 106 potential patients. The study will continue, with the patients currently enrolled, with the co-primary endpoints, Apnea-Hypopnea Index (AHI) and Oxygen Desaturation Index (ODI) responder rates, assessed at 12 months post implant and followed for five years. The Company reorganized its global R&D function and expects to transition all ongoing R&D activities from Israel to the U.S. and Belgium. The Company received notice that Inspire Medical Systems, Inc. ('Inspire') filed a lawsuit against the Company in the United States alleging infringement of certain patents owned by Inspire. The Company is well prepared, has the means and intends to vigorously defend itself in this matter. 'We are pleased with the growth we saw in the second quarter, which provides further evidence that our commercial proof of concept in Germany has been successful,' commented Olivier Taelman, Chief Executive Officer. 'With FDA approval in hand, we expect to take the lessons learned from Germany and apply them to the U.S. as we bring our unique Genio system to the U.S. In addition, we believe that the patient population currently enrolled in the ACCCESS study will provide statistically significant results, which along with the outcomes from prior clinical evidence, will provide meaningful data with respect to the safety and efficacy of using Genio therapy in the patient population suffering from Complete Concentric Collapse ('CCC'). Patients with CCC represent a significant unmet need in the treatment of OSA as no FDA approved treatment currently exists.' The preliminary, unaudited financial results described in this press release, including preliminary revenue and operating expenses for the second quarter of 2025 and preliminary cash, cash equivalents and financial assets as of June 30, 2025, are estimates only. These financial results could change as a result of further review. Accordingly, you should not place undue reliance on this information. Complete financial results for the second quarter of 2025 will be announced and issued on Monday, August 18, 2025 after NASDAQ market close. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q2 2025 Earnings Call Webcast. About Nyxoah Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the U.S. Food and Drug Administration (FDA) for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65. For more information, please visit Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device. FORWARD-LOOKING STATEMENTS Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Company's financial results for the second quarter ended June 30, 2025; the Company's estimates of revenue and operating expenses for the second quarter of 2025 and cash, cash equivalents and financial assets as of June 30, 2025; the Genio system; planned and ongoing clinical studies of the Genio system, including the ACCCESS study; the potential advantages of the Genio system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's plans to transition its ongoing R&D activities to the U.S. and Belgium; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the 'Risk Factors' section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press NyxoahJohn Landry, CFOIR@ For MediaIn United StatesFINN Partners – Alyssa Paldo In International/GermanyMC Services – Anne Hennecke nyxoah@ In Belgium/FranceBackstage Communication – Gunther De Backer gunther@ 531708903v.1 Attachment Preliminary Results 2Q and 1st Half 25 PR-531708903-v5Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Should You Buy Rivian Stock While It's Below $17?
Key Points Rivian's deliveries are stagnating in this challenging macro environment. But it expects the R2's launch to breathe fresh life into its business. Its stock would be undervalued if it can pull off that turnaround. 10 stocks we like better than Rivian Automotive › Rivian (NASDAQ: RIVN) posted its second-quarter earnings report on Aug. 5. The electric vehicle maker's revenue rose 13% year over year to $1.3 billion, exceeding analysts' expectations by $10 million. Its total deliveries declined 23% to 10,661 vehicles, but it offset that pressure with rising software and service revenues. Unfortunately, its gross margin -- which turned green in the first quarter of 2025 -- turned red again in the second quarter. It only produced 5,979 vehicles during the quarter, which marked a 38% drop from a year ago. It narrowed its net loss from $1.5 billion to $1.1 billion, but its loss of $0.80 per share still missed the consensus forecast by $0.16. Rivian's mixed numbers didn't impress the market, and the stock remains 30% below its 52-week high of $17.15 on May 20. Should you buy it before it bounces back? Why isn't Rivian impressing investors? Rivian sells three types of EVs: the R1T pickup, the R1S full-size SUV, and electric delivery vans for its top investor Amazon and other customers. Before its IPO in November 2021, Rivian claimed it could produce 50,000 vehicles in 2022. But this is what actually happened over the the past three and half years: Metric 2022 2023 2024 1H 2025 Vehicles produced 24,337 57,232 49,476 20,590 Vehicles delivered 20,332 50,122 51,579 19,301 Revenue $1.66 billion $4.43 billion $4.97 billion $2.54 billion Net loss ($6.75 billion) ($5.43 billion) ($4.75 billion) ($1.66 billion) Data source: Rivian. Rivian grappled with supply chain constraints in 2022. Its production and deliveries accelerated in 2023 as it overcame those challenges, but its expansion stalled out again in 2024 as rising interest rates chilled the high-end EV market, more competitors carved up the market, and it temporarily shut down its main plant to upgrade its production lines. For 2025, it expects to only deliver 40,000 to 46,000 vehicles. Analysts expect its revenue to rise 6% to $5.29 billion as it slightly narrows its net loss to $3.7 billion. It blames that slowdown on ongoing supply chain challenges, higher tariffs on raw materials and batteries, and another shutdown of its main plant as it gears up for the rollout of its smaller R2 SUV in 2026. That dim near-term outlook is weighing down Rivian's stock. Could Rivian be a deep value play? Rivian is struggling to scale up its business, but it expects the R2's launch to attract a much broader range of customers. It also plans to keep selling its regulatory credits to other automakers while expanding its software and services segment to boost its gross margin. At the end of the second quarter, it still had $8.52 billion in total liquidity -- including $7.51 billion in cash, cash equivalents, and short-term investments. That cash should carry it through the launch of the R2 and help it ramp up production as the macro environment improves. If it can pull that off, analysts expect Rivian's revenue to rise 34% to $7.1 billion in 2026 and grow another 52% to $10.8 billion in 2027. They also expect it to gradually narrow its net losses. With an enterprise value of $13.2 billion, Rivian trades at just 2 times next year's sales. That makes it look like a value play compared to Tesla, which trades at 9 times next year's sales. Therefore, any positive news could cause Rivian's stock to double or triple -- and it would still be considered reasonably valued relative to its growth potential. That might be why insiders bought slightly more shares than they sold over the past 12 months. Amazon also hasn't sold any of its shares in Rivian since its IPO, and Rivian is still supported by other big investors like Porsche and the Saudi Arabian conglomerate Abdul Latif Jameel. Rivian is still a highly speculative stock, and there's no guarantee it can overcome its growing pains and evolve into another EV giant like Tesla. But if it gets its act together, expands its addressable market with the R2, and ramps up production, it could eventually command a much higher valuation. So if you have faith in Rivian's long-term growth plans, then it's worth accumulating while it trades so far below its 52-week high. Do the experts think Rivian Automotive is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Rivian Automotive make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,060% vs. just 182% for the S&P — that is beating the market by 877.64%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Leo Sun has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Tesla. The Motley Fool recommends Porsche Automobil Se. The Motley Fool has a disclosure policy. Should You Buy Rivian Stock While It's Below $17? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
